Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personalizing Plavix: Eric Topol Champions Genotyping For Stent Patients

This article was originally published in The Gray Sheet

Executive Summary

Genotyping patients to help optimize treatment with the widely prescribed anti-clotting drug clopidogrel can be a successful model for the nascent pharmacogenetic testing market, according to Scripps Health exec and cardiologist Eric Topol

You may also be interested in...



Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report

A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.

Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report

A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.

In Vitro Diagnostics: The Quest For Growth

This article first appeared in Medtech Insight, October 2010.

Related Content

Topics

UsernamePublicRestriction

Register

MT028735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel